No­var­tis pulls the plug on UK-based car­dio­vas­cu­lar study

No­var­tis is call­ing off a UK-based tri­al for Leqvio in the pri­ma­ry pre­ven­tion of car­dio­vas­cu­lar events in pa­tients with high cho­les­terol, the com­pa­ny con­firmed on Wednes­day.

The Swiss phar­ma gi­ant made the de­ci­sion af­ter “care­ful eval­u­a­tion,” a spokesper­son told End­points News via email. The tri­al, dubbed ORI­ON-17, was planned in part­ner­ship with Eng­land’s Na­tion­al Health Ser­vice (NHS) and was part of the com­pa­ny’s strat­e­gy to es­tab­lish Leqvio as a stan­dard of care in car­dio­vas­cu­lar dis­ease man­age­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER